- Home
- BV vs RIGL Comparison
BV vs RIGL Comparison
Compare BV & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BV | RIGL |
|---|---|---|
| Founded | 1939 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 884.9M |
| IPO Year | 2018 | 2000 |
Fundamental Metrics
Financial Performance| Metric | BV | RIGL |
|---|---|---|
| Price | $10.16 | $46.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 5 |
| Target Price | $15.45 | ★ $63.00 |
| AVG Volume (30 Days) | ★ 780.8K | 156.8K |
| Earning Date | 11-18-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $3.21 | $3.89 |
| Revenue Next Year | $0.18 | $21.95 |
| P/E Ratio | ★ N/A | $37.33 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $9.82 | $24.84 |
| 52 Week High | $15.00 | $52.24 |
Technical Indicators
Market Signals| Indicator | BV | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 36.88 | 54.74 |
| Support Level | $9.82 | $43.78 |
| Resistance Level | $11.99 | $49.50 |
| Average True Range (ATR) | 0.32 | 1.61 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 22.15 | 65.54 |
Price Performance
Historical ComparisonAbout BV BrightView Holdings Inc.
BrightView Holdings Inc is a provider of commercial landscaping services in the United States. The company provides commercial landscaping services, landscape maintenance, and enhancements to tree care and landscape development. It operates through two segments namely Maintenance Services, and Development Services. The Maintenance Services are self-performed through a national branch network and are route-based in nature. It includes mowing, gardening, mulching and snow removal, water management etc. And Development Services are comprised of sophisticated design, coordination, and installation of landscapes at recognizable corporate, athletic, and university complexes. The company generates a majority of its revenue from Maintenance Services.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.